The Latest Breaking News from Pfizer

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.

"Emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains"

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have 

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Here's a roundup of top developments in the biotech space over the last 24 hours.

Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant

Omicron's rise has forced vaccine makers to reassess the effectiveness of their vaccines.

Company hopes vaccine will be ready for approval by March; UK reports 439 deaths and more than nearly 95,000 cases

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.